Fungal infections are a serious health threat to humans, particularly those with weakened immune systems. Safer and more effective antifungal drugs are needed. One of the key agents causing fungal diseases is the yeast known as Candida albicans. By studying the genome of Candida albicans, this project proposes to find all of the genes essential to the life of this fungal pathogen, thereby identifying new targets for drug therapies.
Co-project leader:
| Bo | Jiang | Merck Frosst Canada Ltd. |
Co-applicant:
| Phil | Youngman | Merck Frosst Canada Ltd. |